Archive · 25 Dec 2025
Novo Nordisk Evaluates Wegovy Oral Pill Rollout in India
Novo Nordisk, a Danish drug company, has a new pill called Wegovy that helps people lose weight.
The US government recently approved this pill, and the company plans to sell it in the US early next year.
They are also talking to other countries in Europe about selling it there.
In India, Novo Nordisk already sells a different form of Wegovy that you inject, but they are still deciding if and when they will sell the new pill there.
The pill has been tested and shown to help people lose a lot of weight, similar to the injectable version.
The company is thinking about how to make it available in India, but they need to make some decisions and get approvals first.
Novo Nordisk's oral Wegovy pill approved by US FDA for weight management.
US launch expected in early January 2026, with filings submitted to European authorities.
India launch under evaluation, subject to internal decisions and regulatory approvals.
Oral semaglutide 25 mg showed mean weight loss of 16.6% in clinical trials.
Injectable Wegovy already launched in India, with prices ranging from ₹11,000 to ₹26,000 per month.
- Who
- Novo Nordisk
- What
- Evaluation of oral Wegovy pill rollout in India
- When
- After US approval and expected US launch in early January 2026
- Where
- India, US, Europe
- Why
- To reduce excess body weight, maintain long-term weight loss, and lower cardiovascular risk
- Company
- Novo Nordisk
- Drug Name
- Wegovy (oral semaglutide 25 mg)
- Approval Authority
- US FDA
- Expected US Launch
- Early January 2026
- Weight Loss
- Mean 16.6% in clinical trials
- India Launch Status
- Under evaluation
- Injectable Wegovy Price in India
- ₹11,000 to ₹26,000 per month
